Shares of uniQure (QURE) experienced a substantial rally, soaring 78.4% on June 17, following an announcement that the U.S. Food and Drug Administration (FDA) has indicated that three-year data from the Phase I/II study of its investigational gene therapy, AMT-130, could serve as the primary basis for a Biologics License Application (BLA) seeking accelerated approval for Huntington’s disease. This pivotal regulatory development, revealed after a recent Type B meeting, signals a potential expedited path to market for the therapy, despite the stock paring back 3.9% on June 18.
Regulatory Pathway Cleared for AMT-130
The FDA’s guidance marks a crucial turning point for uniQure’s AMT-130 program. The agency informed uniQure that the comprehensive three-year data from the ongoing Phase I/II study is deemed sufficient to underpin a BLA submission for accelerated approval. This decision provides a clearer regulatory roadmap for the gene therapy, which targets the debilitating neurodegenerative disorder, Huntington’s disease.
While the FDA has endorsed the data’s sufficiency, it has also emphasized the need for alignment on the design of a confirmatory study. Specifically, the agency seeks to incorporate a concurrent standard-of-care control group, moving away from a sham-controlled design. uniQure expects to receive the final minutes from the Type B meeting within 30 days and is committed to finalizing these plans expeditiously with the FDA. The company anticipates achieving full alignment with the regulatory body ahead of its projected BLA filing in the third quarter of 2026, with a commitment to initiating the confirmatory study as quickly as possible.
Overcoming Previous Hurdles
This positive regulatory feedback comes as a significant relief to investors, especially considering a prior setback earlier in 2026. In March 2026, uniQure’s shares experienced a decline after the company disclosed that the FDA, following a Type A meeting in January 2026 and a pre-BLA meeting in October 2025, had not agreed that data from the Phase I/II studies, when compared with an external control group, were sufficient as primary evidence of effectiveness for a marketing application. At that time, the FDA had recommended a prospective, randomized, double-blind, sham surgery-controlled study. The current update indicates a successful navigation of these previous regulatory complexities, with the FDA now acknowledging the strength of the three-year data.
AMT-130: A Novel Gene Therapy Approach
AMT-130 represents a novel investigational gene therapy leveraging uniQure’s proprietary miQURE platform. The therapy is designed to employ a microRNA (miRNA) to silence the huntingtin gene, which is implicated in Huntington’s disease, and specifically target the potentially highly toxic exon 1 protein fragment. This innovative approach aims to address the root cause of the disease.
The therapy is currently being evaluated across two ongoing multi-center, dose-escalating Phase I/II studies. These studies are designed to assess AMT-130’s safety, tolerability, and exploratory efficacy signals in patients with Huntington’s disease. In the United States, the Phase I/II study enrolled 26 patients with early manifest Huntington’s disease, who were randomized to receive either a low dose (n=6), a high dose (n=10) of AMT-130, or a sham procedure (n=10). Treatment involved a one-time administration of AMT-130 via MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum. The U.S. study includes a 12-month blinded phase followed by five years of unblinded long-term follow-up for treated patients, with an additional four control patients having crossed over to treatment.
Concurrently, an open-label Phase Ib/II study in Europe enrolled 13 patients with early manifest Huntington’s disease, comprising six receiving the low dose and seven receiving the high dose. Beyond these, uniQure has enrolled 12 additional patients across U.S. and European sites in a third cohort, evaluating both dose levels in combination with immunosuppression. A fourth U.S.-based cohort of six patients is assessing the high-dose regimen in patients with lower striatal volumes. AMT-130 has garnered significant recognition from the FDA, receiving Regenerative Medicine Advanced Therapy (RMAT) designation—the first ever granted to a Huntington’s disease therapy—along with Breakthrough Therapy and Fast Track designations.
Broader Pipeline and Market Context
Huntington’s disease is a devastating genetic disorder characterized by the progressive breakdown of nerve cells in the brain, leading to severe declines in cognitive and physical abilities, including movement, thinking, and psychiatric problems. A potential approval of AMT-130 would represent a significant therapeutic advancement for patients with this unmet medical need and a substantial boost for uniQure.
Beyond AMT-130, uniQure’s pipeline includes AMT-260, currently in a Phase I/IIa study for refractory mesial temporal lobe epilepsy (MTLE), and AMT-191 for Fabry disease. The company also markets Hemgenix, an internally developed gene therapy for hemophilia B, in partnership with CSL Behring, in the United States and the EU. This broader portfolio underscores uniQure’s commitment to gene therapy development.
The year-to-date performance of QURE shares reflects investor optimism, with the stock surging 93.4% against an industry decline of 1.8%. The FDA’s latest endorsement of AMT-130 data for an accelerated approval filing path significantly de-risks the program and positions uniQure for a potentially transformative period, offering hope for patients and a strong outlook for the company’s future.
